Compare Danaher Corporation (DHR) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Herbalife Nutrition Ltd — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B). The key difference: Danaher Corporation is far larger — about 118.6× Herbalife Nutrition Ltd's market cap, and Danaher Corporation pays a 0.77% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| DHR | HLF | |
|---|---|---|
Market Cap | $145.83B | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $242.05 | $19.96 |
52-Week Low | $161.91 | $7.75 |
Enterprise Value | $168.04B | $3.06B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.
The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
